Back to results
US 2026/0085058 A1Published application
Degraders of son of sevenless homolog 1
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsYu YUAN, Hao XIE
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compounds which are degraders of son of sevenless homolog 1 (SOS1) and their use in treating cancers, in particular KRAS-mutant cancers.
Claims22
A compound of Formula I or Formula II
- or a pharmaceutically acceptable salt or derivative thereof,
- wherein:
- R1 is aryl optionally substituted with one or more groups independently selected from halo, amino, C1-C6 alkyl, and C1-C6 haloalkyl;
- R2 is selected from H or C1-C6 alkyl;
- R3 and R4 are each C1-C6 alkoxy;
- L is a linker;
- and
- B is an E3 ubiquitin ligase-recruiting moiety.
5 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.